About US
Contact us
-
Big Pharma shuns dirt-cheap cancer drugPatients with Type 2 diabetes taking metformin are less likely to develop some forms of cancer, and that has a lot of folks really excited in drug research. But that feeling doesn't carry over to Bi2012/9/27
-
Coca-Cola coaches African health officials on drug-and-vax distributionNovartis ($NVS) CEO Joe Jimenez is only one pharma executive who figures the industry can learn a thing or two from consumer goods. Now, the Bill & Melinda Gates Foundation is expanding a vaccine-2012/9/26
-
Is Valeant's $2.6B price for Medicis too high?Valeant Pharmaceuticals ($VRX) CEO Michael Pearson has a penny-pinching reputation. When it comes to making deals, Pearson drives a hard bargain--or he walks away. But analysts are wondering whether P2012/9/26
-
Regeneron, Vertex, J&J score high in employer rankingsDrugmakers ranked among the world's top employers in two rankings:Science's 2012 survey tagged Regeneron ($REGN) as the best biopharma employer, with Vertex Pharmaceuticals ($VRTX) in second place and2012/9/25
-
Private equity owners put for-sale sign on U.K.'s RosemontShopping for a drug company that's adept at making liquid formulas? You're in luck, because privately held Rosemont Pharmaceuticals is on the block. Owned by Close Brothers Private Equity, the drugmak2012/9/25
-
Report says Canadian drug market getting hCanadamay not have a huge drug market for pharma to target, but it has a growing one. That is the forecast from consulting firm GlobalData, which projects drug sales more than doubling to $45.9 billio2012/9/24
-
UPDATED: EU gives recommendation for Regeneron's EyleaRegeneron Pharmaceuticals ($REGN)has been giving Roche($RHHBY)fits with itsEyleadrug, stealing market share from the Swiss drugmaker'sLucentis. It appears that Regeneron will battle Lucentis in a new2012/9/24
-
Report: Roche's Zelboraf, BMS' Yervoy control their segmentA new market report saysYervoyfrom Bristol-Myers Squibb ($BMY) andZelboraffrom Roche ($RHHBY) have sewn up two-thirds of the market for treating advanced malignantmelanomaand will underpin significant2012/9/24
-
Bayer takes aim at J&J's Evra with new birth control patchBayer, already one of the biggest players in the $8 billion a yearcontraceptivedrug market, is aiming to take on Johnson & Johnson ($JNJ) in Europe with a transparentbirth controlpatch. The Germa2012/9/21
-
Roche hands NYC a biotech coup with new R&D siteSo long, Nutley. Hello, Big Apple. Roche ($RHHBY) is moving its whittled-down East Coast R&D group from New Jersey to a new life sciences complex in Manhattan, which beat out some fierce competiti2012/9/21